Therapeutic area
Cardiovascular and metabolic
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
33
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
168
Industry-sponsored
Recruiting Phase 3
192
Industry-sponsored
Recruiting Phase 4 (post-approval)
28
Industry-sponsored
Recent approvals
- Sunharbo (Asundexian) · Bayer Healthcare NovelPriority reviewNov 9, 2026
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
- Onswik (Insulin Efsitora Alfa-Gobe) · Eli Lilly and CO NovelSep 23, 2026
To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
- Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd. Sep 15, 2026
- Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd. Jul 24, 2026
- Lipfendra (Enlicitide Decanoate) · Msd NovelPriority reviewJul 15, 2026
To reduce low-density lipoprotein cholesterol
- Baxfendy (Baxdrostat) · Astrazeneca Ab NovelPriority reviewMay 15, 2026
To treat hypertension in combination with other antihypertensive drugs
- Langlara (Insulin Glargine-Aldy) · Sunshine Lake Pharma CO LTD Apr 29, 2026
- Foundayo (Orforglipron Calcium) · Eli Lilly and CO NovelApr 1, 2026
To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
- Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INC NovelOrphanMar 26, 2026
- Yartemlea (Narsoplimab-Wuug) · Omeros Corp NovelBreakthrough therapyPriority reviewOrphanDec 23, 2025
To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
- Myqorzo (Aficamten) · Cytokinetics NovelBreakthrough therapyOrphanDec 19, 2025
To treat symptomatic obstructive hypertrophic cardiomyopathy
- Cardamyst (Etripamil) · Milestone Pharms USA NovelDec 12, 2025
To treat episodes of paroxysmal supraventricular tachycardia
- Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc. NovelDec 12, 2025
To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise
- Redemplo (Plozasiran Sodium) · Arrowhead NovelBreakthrough therapyOrphanNov 18, 2025
To reduce triglycerides in adults with familial chylomicronemia syndrome
- Evkeeza (Evinacumab-Dgnb) · Regeneron Pharmaceuticals Breakthrough therapyPriority reviewOrphanSep 25, 2025
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- REGN7508CenvacibartPhase 312 trials
Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
Largest recruiting Phase 3 trials
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07626411 · 15,364 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 11, 2029
Drug: REGN7508; Apixaban and 1 more · For: Atrial Fibrillation (AF)
Sites: Alexander City, Alabama; Dothan, Alabama; Fairhope, Alabama · 84 sites in all
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06677060 · 11,300 participants (planned) · Start Mar 14, 2025 · Primary completion Dec 17, 2029
Drug: Baxdrostat and dapagliflozin · For: Heart Failure
Sites: Birmingham, Alabama; Centreville, Alabama; Fairhope, Alabama · 977 sites in all
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07181109 · 11,000 participants (planned) · Start Sep 6, 2025 · Primary completion Sep 23, 2030
Drug: Zilebesiran; Placebo · For: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 1,226 sites in all
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07241390 · 7,140 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 2031
Drug: Orforglipron; Placebo · For: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina · 566 sites in all
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07761117 · 6,950 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 3, 2029
Drug: Elecoglipron; Placebo · For: Heart Failure With Preserved Ejection Fraction (HFpEF); Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Sites: Fairhope, Alabama; Anchorage, Alaska; Gilbert, Arizona · 679 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06424288 · 6,712 participants (planned) · Start Jun 17, 2024 · Primary completion May 22, 2028
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Mobile, Alabama; Chula Vista, California; Orange, California · 672 sites in all
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07567001 · 5,610 participants (planned) · Start May 11, 2026 · Primary completion Jul 23, 2029
Drug: NNC0487-0111; Placebo · For: Obesity; Heart Failure
Sites: Alexander City, Alabama; Birmingham, Alabama; Fairhope, Alabama · 838 sites in all
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07037459 · 5,056 participants (planned) · Start Jun 25, 2025 · Primary completion Jun 30, 2028
Drug: Maridebart cafraglutide; Placebo · For: Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity
Sites: Birmingham, Alabama; Dothan, Alabama; Fairhope, Alabama · 686 sites in all
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.